Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours.
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
Positions Curium as leading manufacturer of Lu-177 isotope
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Subscribe To Our Newsletter & Stay Updated
